-
Mashup Score: 12ASCO Plenary Series Program - 9 month(s) ago
Learn more about the faculty and program for the July Plenary Series session.
Source: old-prod.asco.orgCategories: Latest Headlines, Partners & KOLsTweet
-
Mashup Score: 8Program Guide – ASCO Meeting Program Guide - 9 month(s) ago
Brian M. Slomovitz Mount Sinai Medical Center, Miami Beach, FL Brian M. Slomovitz, Jose Alejandro Perez-Fidalgo, Erika P. Hamilton, Giorgio Valabrega, Toon Van Gorp, Jalid Sehouli, Jaroslav Klat, Tally Levy, Stephen Welch, Debra L. Richardson, Eva Maria Guerra Alia, Giovanni Scambia, Stephanie Henry, Pauline Wimberger, Jeronimo Martinez, Bradley J. Monk, Pratheek Kalyanapu, Mansoor Raza Mirza, Vicky Makker, Ignace Vergote Mount Sinai Medical Center, Miami Beach, FL, GEICO. Hospital Clinico Universitario
Source: meetings.asco.orgCategories: Latest Headlines, Partners & KOLsTweet
-
Mashup Score: 0Monthly Plenary Series - 10 month(s) ago
The ASCO Plenary Series is a monthly online forum for presentation and discussion of the latest cancer research that keeps clinicians current on new and emerging research in between meetings. The Plenary Series provides faster dissemination of practice-changing science to better help clinicians deliver the most up-to-date care and treatments to patients with cancer. Each monthly program features…
Source: ASCOCategories: Latest Headlines, UrologyTweet
-
Mashup Score: 0ASCO Plenary Series Program - 10 month(s) ago
Learn more about the faculty and program for the July Plenary Series session.
Source: ASCOCategories: Latest Headlines, Partners & KOLsTweet
-
Mashup Score: 0Neotorch Trial: Toripalimab Plus Chemotherapy Improves Event-Free Survival in Resectable Stage III NSCLC - The ASCO Post - 11 month(s) ago
Findings from a phase III, randomized trial highlight the benefit derived from perioperative immunotherapy in patients with early-stage resectable non–small cell lung cancer (NSCLC), according to data presented during the ASCO Plenary Series: April 2023 Session.1 Interim analysis of the Neotorch study showed a significant improvement in event-free survival for patients with resectable stage III…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Call for Papers - 1 year(s) ago
Call for Papers
Source: asco.confex.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Perioperative Toripalimab/Chemotherapy Combo Improves EFS in Resectable Stage III NSCLC - 1 year(s) ago
Perioperative toripalimab plus chemotherapy generated a median event-free survival benefit vs placebo plus chemotherapy in patients with resectable stage III non–small cell lung cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Program Guide – ASCO Meeting Program Guide - 1 year(s) ago
AuthorsSteven SorscherWake Forest School of Medicine, Winston-Salem, NCSteven Sorscher, Jaclyn LoPiccolo, Elaine Chen, Brandie Heald, Scott T. Michalski, Sarah M. Nielsen, Robert Luke Nussbaum, Renato G. Martins, Edward D. EsplinOrganizationsWake Forest School of Medicine, Winston-Salem, NC, Dana–Farber Cancer Institute, Boston, MA, Invitae, San Francisco, CA, University of Washington, Seattle,…
Source: meetings.asco.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 16American Association for Cancer Research (AACR) 2023 Highlights from Community Oncology – ONC Brothers - 1 year(s) ago
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and…
Source: oncbrothers.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2KRYSTAL-1 Update: Adagrasib Yields Benefit in Variety of KRAS G12C–Mutated Tumors - The ASCO Post - 1 year(s) ago
By Caroline Helwick Posted: 4/26/2023 9:45:00 AM Last Updated: 4/26/2023 10:14:55 AM In the phase I/II KRYSTAL-1 trial, the KRAS inhibitor adagrasib demonstrated promising clinical activity in previously treated patients with pancreatic ductal adenocarcinoma, biliary tract cancer, and other solid tumors…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
‼️ Tune in today, 7/25, at 3 PM ET for the July #ASCOPlenarySeries session featuring new phase 3 results in #endometrialcancer from @GynCancerMD followed by an expert discussion and Q&A. Details ➡️ https://t.co/DfK629EDcm #gyncsm @OncoAlert @DrHelenMacKay @DrMMurphy https://t.co/pQt36DKDrB